• Genizon BioSciences Inc., of Montreal, raised C$31 million (US$31.2 million) in a Series E financing. Biotech Turnaround Fund BV led the round, which also included existing investors. Proceeds will be used to enhance Genizon's GeneMap technology, which provides maps of genes and biomarkers associated with various diseases, as well as to conduct the genomewide association studies needed to create GeneMaps for diseases associated with metabolic syndrome.

• Orexigen Therapeutics Inc., of San Diego, filed a registration statement for 7 million shares of common stock. Based on a recent trading price (NASDAQ:OREX) of $13.94, the company estimated net proceeds at $90.6 million, which will be used to fund clinical trials of Contrave (Bupropion SR/Naltrexone SR) and Emphatic (Bupropion SR/Zonisamide SR) for obesity, as well as other programs. Certain shareholders plan to offer an additional 1.05 million shares to cover overallotments. Merrill Lynch & Co. is acting as sole book-running manager for the offering, with Leerink Swann LLC serving as co-lead manager and JMP Securities LLC, Lazard Capital Markets, Canaccord Adams Inc. and Natixis Bleichroeder Inc. acting as co-managers.

No Comments